Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candoxatrilat SCHEMBL9469695 | 1.00 | MME (1.00) | MME | |
| Candoxatrilat SCHEMBL389958 | 1.00 | MME (1.00) | MME | |
| Candoxatrilat SCHEMBL389959 | 1.00 | MME (1.00) | MME | |
| SCHEMBL9469210 | 0.92 | MME (0.85) | MME | |
| SCHEMBL9469212 | 0.92 | MME (0.85) | MME | |
| SCHEMBL7449192 | 0.91 | MME (0.84) | MME | |
| SCHEMBL9106667 | 0.90 | MME (0.82) | MME | |
| SCHEMBL9469562 | 0.90 | MME (0.81) | MME | |
| SCHEMBL9469559 | 0.90 | MME (0.81) | MME | |
| SCHEMBL9469563 | 0.90 | MME (0.81) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4595974-A2 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE | Carlson, William D. (US) | 2025-08-06 | — | — | EP | claimed |
| US-20240123033-A1 | THERAPEUTIC COMBINATIONS OF TDFRPs AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS | Therapeutics By Design, LLC (US) | 2024-04-18 | — | — | US | claimed |
| EP-4308587-A1 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS | Therapeutics by Design, LLC (US) | 2024-01-24 | — | — | EP | claimed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | claimed |
| US-11759465-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| WO-2022265697-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | Tiger Development, LLC (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220370360-A1 | COMPOSITIONS FOR TREATING VIRAL INFECTIONS AND METHODS FOR SAME | ACCESS TO ADVANCED HEALTH INSTITUTE | 2022-11-24 | — | — | US | claimed |
| WO-2022197842-A1 | METHODS OF TREATING PULMONARY FIBROSIS ASSOCIATED WITH VIRAL INFECTION USING TISSUE DIFFERENTIATION FACTOR RELATED POLYPEPTIDES (TDFRPS) | Therapeutics By Design, LLC (US) | 2022-09-22 | — | — | WO | claimed |
| WO-2022197855-A1 | THERAPEUTIC COMBINATIONS OF TDFRPS AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS | Therapeutics By Design, LLC (US) | 2022-09-22 | — | — | WO | claimed |
| US-20040192584-A1 | Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor | PHARMACIA CORPORATION | 2004-09-30 | — | — | US | claimed |
| WO-2004082636-A2 | COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND A NEUTRAL ENDOPEPTIDASE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| US-20030050301-A1 | Combination of aldose reductase inhibitors and angiotensin-II antagonists for the treatment of diabetic nephropathy | MYLARI BANAVARA L (US) | 2003-03-13 | — | — | US | claimed |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | MASSACHUSETTS COLLEGE OF PHARMACY | 2002-08-22 | — | — | US | claimed |
| US-20020068740-A1 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | MYLARI BANAVARA L (US) | 2002-06-06 | — | — | US | claimed |
| EP-1106210-A2 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| US-5192800-A | Hypotensive agents | PFIZER INC. (US) | 1993-03-09 | — | — | US | claimed |
| EP-0342850-B1 | ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1992-05-20 | — | — | EP | claimed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | claimed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192584-A1 | Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor | MME, REN, ACE | MME 1/4885 |
| US-20030050301-A1 | Combination of aldose reductase inhibitors and angiotensin-II antagonists for the treatment of diabetic nephropathy | REN, AGTR2, AGTR1 | MME 54/4885 |
| US-20020068740-A1 | Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications | AKR1B1, AKR1C4, AKR1C2 | MME 192/4885 |
| US-20020115655-A1 | Such as S-(4-methoxybenzyl)-N-(2-(N',N'-dimethylamino)ethyl) thiosalicylamide; for treatment of cardiovascular disorders | CACNA1G, CACNA1F, CACNA1H | MME 263/4885 |
| US-20230338385-A1 | NOVEL USES | ADORA2A, ATP2A1, ADORA2B | MME 1308/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | MME 2037/4885 |
| US-11759465-B2 | Uses | ADORA2A, ADORA2B, ADORA1 | MME 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.